Key Points
- Insider sale: Aura Biosciences insider Anthony Gibney sold 12,824 shares at an average price of $6.42, totaling about $82,330. The filing says the sale was to cover tax withholding obligations tied to vesting equity awards.
- Recent performance and earnings: The stock opened at $6.28, near its 200-day average of $6.34 but below its 50-day average of $7.22. Aura also recently reported a quarterly loss of $0.50 per share, missing analyst estimates.
- Analyst sentiment: Wall Street analysts currently have a consensus rating of Hold on Aura Biosciences, with an average price target of $20.50. Ratings are mixed, with two Buy ratings, one Hold, and one Sell.
Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Anthony Gibney sold 12,824 shares of the firm's stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $6.42, for a total transaction of $82,330.08. Following the completion of the transaction, the insider directly owned 265,354 shares in the company, valued at approximately $1,703,572.68. The trade was a 4.61% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Aura Biosciences Stock Performance
Shares of NASDAQ AURA opened at $6.28 on Wednesday. Aura Biosciences, Inc. has a fifty-two week low of $4.73 and a fifty-two week high of $9.53. The stock has a market cap of $649.29 million, a price-to-earnings ratio of -3.61 and a beta of 0.39. The firm's 50-day simple moving average is $7.22 and its 200 day simple moving average is $6.34.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.10). On average, sell-side analysts predict that Aura Biosciences, Inc. will post -1.73 EPS for the current year.
Institutional Investors Weigh In On Aura Biosciences
Large investors have recently modified their holdings of the stock. Parallel Advisors LLC increased its stake in shares of Aura Biosciences by 130.4% during the 1st quarter. Parallel Advisors LLC now owns 5,665 shares of the company's stock worth $38,000 after purchasing an additional 3,206 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock worth $40,000 after purchasing an additional 2,104 shares during the last quarter. ProShare Advisors LLC purchased a new stake in shares of Aura Biosciences during the 4th quarter worth approximately $59,000. Water Island Capital LLC purchased a new stake in shares of Aura Biosciences during the 3rd quarter worth approximately $64,000. Finally, 49 Wealth Management LLC purchased a new stake in shares of Aura Biosciences during the 3rd quarter worth approximately $66,000. Hedge funds and other institutional investors own 96.75% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. Wall Street Zen raised shares of Aura Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, April 4th. Leerink Partners set a $17.00 target price on shares of Aura Biosciences in a research report on Tuesday, May 12th. HC Wainwright lifted their target price on shares of Aura Biosciences from $22.00 to $24.00 and gave the stock a "buy" rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings raised shares of Aura Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $20.50.
View Our Latest Analysis on AURA
About Aura Biosciences
(
Get Free Report)
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
